Greenleaf Trust boosted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 12.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,053 shares of the biopharmaceutical company’s stock after acquiring an additional 2,050 shares during the period. Greenleaf Trust’s holdings in Bristol-Myers Squibb were worth $1,121,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the business. GWM Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $643,000. Intact Investment Management Inc. raised its position in shares of Bristol-Myers Squibb by 3.7% in the third quarter. Intact Investment Management Inc. now owns 85,100 shares of the biopharmaceutical company’s stock valued at $5,282,000 after purchasing an additional 3,000 shares during the period. Price Capital Management Inc. bought a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $1,633,000. Kendall Capital Management bought a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $360,000. Finally, Spectrum Asset Management Inc. NB CA bought a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $841,000. 72.90% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb stock traded down $0.32 during midday trading on Thursday, reaching $53.20. 6,934,601 shares of the stock were exchanged, compared to its average volume of 9,604,413. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. Bristol-Myers Squibb Co has a 52 week low of $46.94 and a 52 week high of $70.05. The firm has a market capitalization of $87.36 billion, a PE ratio of 17.67, a price-to-earnings-growth ratio of 1.49 and a beta of 1.08.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Research analysts forecast that Bristol-Myers Squibb Co will post 3.87 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Friday, October 5th were paid a $0.40 dividend. The ex-dividend date was Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a yield of 3.01%. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.
Several research firms have recently issued reports on BMY. SunTrust Banks reissued a “buy” rating and issued a $67.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, July 31st. JPMorgan Chase & Co. boosted their price target on shares of Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, October 8th. BMO Capital Markets boosted their price target on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company a “market perform” rating in a research report on Friday, November 16th. Societe Generale set a $47.00 price target on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Wednesday, November 14th. Finally, William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, October 22nd. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $61.84.
TRADEMARK VIOLATION WARNING: “Greenleaf Trust Increases Stake in Bristol-Myers Squibb Co (BMY)” was published by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://theenterpriseleader.com/2018/11/22/bristol-myers-squibb-co-bmy-position-lifted-by-greenleaf-trust.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
See Also: How mutual funds make money
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.